Novel lipid gene signature for MRD in Ovarian Cancer

Applications: To identify new targets for therapy in minimal residual disease.

Following chemotherapy, multiple residual disease (MRD) is capable of re-initiating tumours and causing recurrence. Until now, the molecular characterisation of solid tumour MRDs has remained elusive.
Researchers at Oxford have discovered that MRD cells are typically characterised by an adipocyte-like gene expression signature and a portion of them will undergo epithelial mesenchymal transition (EMT).

Features	Benefits
The discovery of an MRD-specific gene signature, which is involved in lipid metabolism.	The discovery identifies inhibitors of lipid metabolism, e.g., fatty acid oxidation (FAO) inhibitors, as potential therapeutic modalities for treating ovarian cancer minimal residual disease.
Sequencing data has discovered that all patients with ovarian MRD express this gene signature, with 75% expressing it to a high level.	Can be used to inform clinicians whether a patient may need additional drug therapy following a course of chemotherapy. Patients will benefit from additional therapy.
Can be used as a tool for pharma companies to screen their existing drug pipeline.	May facilitate the discovery of specific pipeline drugs which are effective at treating patients with ovarian MRD.
The lipid gene signature could be used as a biomarker to select suitable patients for clinical trials.	Patients with the gene signature could be selected for clinical trials testing the efficacy of FAO inhibitors in the treatment of ovarian cancer MRD.

Patented & Available for:

Licensing
Co-development
Consulting

Request more information
about this technology

Back to Technologies Available

Technologies for License

Novel lipid gene signature for MRD in Ovarian Cancer

Ready to get in touch?